垂体依赖性皮质醇过多症犬的 ACTH 后皮质醇与曲托司坦用量之间的关系

IF 1.9 2区 农林科学 Q2 AGRICULTURE, DAIRY & ANIMAL SCIENCE
Fernanda Nastri Gouvêa , Alessandra Martins Vargas , Ednaldo Carvalho Guimarães , Leandro Zuccolotto Crivellenti , Caio Santos Pennacchi , Hévila Dutra Barbosa de Cerqueira , Luana de Oliveira Branco , Natani Silva Reis , Sofia Borin-Crivellenti
{"title":"垂体依赖性皮质醇过多症犬的 ACTH 后皮质醇与曲托司坦用量之间的关系","authors":"Fernanda Nastri Gouvêa ,&nbsp;Alessandra Martins Vargas ,&nbsp;Ednaldo Carvalho Guimarães ,&nbsp;Leandro Zuccolotto Crivellenti ,&nbsp;Caio Santos Pennacchi ,&nbsp;Hévila Dutra Barbosa de Cerqueira ,&nbsp;Luana de Oliveira Branco ,&nbsp;Natani Silva Reis ,&nbsp;Sofia Borin-Crivellenti","doi":"10.1016/j.domaniend.2024.106871","DOIUrl":null,"url":null,"abstract":"<div><p>Trilostane is the current treatment of choice for managing pituitary-dependent hypercortisolism (PDH) in dogs. While prescribing higher initial doses may elevate the risk of iatrogenic hypocortisolism, opting for more conservative approach could result in delayed disease control, since most individuals end up requiring dosage increases. The adrenocorticotrophin stimulation test (ACTHst), a widely recognized hormonal test for assessing adrenal function, is an essential tool for monitoring the pharmacological treatment of canine hypercortisolism (CH) that can also be used for diagnostic purposes. The aim of this study was to investigate the relationship between post-ACTH cortisol (cpACTH) at PDH diagnosis and the required trilostane dose for sign control and endogenous cortisol regulation in dogs, considering a hypothesis that higher serum cpACTH concentration would necessitate a higher trilostane dosage for disease management. Data for 43 dogs with PDH had their diagnostic cpACTH recorded and correlated to the trilostane dosage necessary to control clinical signs and achieve satisfactory cortisol levels (ideally 2-7 μg/dL). The odds ratio (p=0.042) suggests that dogs with cpACTH ≥ 27 μg/dL at diagnosis are 96% more likely to need a higher trilostane dosage for achieving satisfactory control of PDH. Thus, cpACTH was found to be associated with the final trilostane dose for controlling PDH in dogs.</p></div>","PeriodicalId":11356,"journal":{"name":"Domestic animal endocrinology","volume":"89 ","pages":"Article 106871"},"PeriodicalIF":1.9000,"publicationDate":"2024-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between post-ACTH cortisol and trilostane dosage in dogs with pituitary-dependent hypercortisolism\",\"authors\":\"Fernanda Nastri Gouvêa ,&nbsp;Alessandra Martins Vargas ,&nbsp;Ednaldo Carvalho Guimarães ,&nbsp;Leandro Zuccolotto Crivellenti ,&nbsp;Caio Santos Pennacchi ,&nbsp;Hévila Dutra Barbosa de Cerqueira ,&nbsp;Luana de Oliveira Branco ,&nbsp;Natani Silva Reis ,&nbsp;Sofia Borin-Crivellenti\",\"doi\":\"10.1016/j.domaniend.2024.106871\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><p>Trilostane is the current treatment of choice for managing pituitary-dependent hypercortisolism (PDH) in dogs. While prescribing higher initial doses may elevate the risk of iatrogenic hypocortisolism, opting for more conservative approach could result in delayed disease control, since most individuals end up requiring dosage increases. The adrenocorticotrophin stimulation test (ACTHst), a widely recognized hormonal test for assessing adrenal function, is an essential tool for monitoring the pharmacological treatment of canine hypercortisolism (CH) that can also be used for diagnostic purposes. The aim of this study was to investigate the relationship between post-ACTH cortisol (cpACTH) at PDH diagnosis and the required trilostane dose for sign control and endogenous cortisol regulation in dogs, considering a hypothesis that higher serum cpACTH concentration would necessitate a higher trilostane dosage for disease management. Data for 43 dogs with PDH had their diagnostic cpACTH recorded and correlated to the trilostane dosage necessary to control clinical signs and achieve satisfactory cortisol levels (ideally 2-7 μg/dL). The odds ratio (p=0.042) suggests that dogs with cpACTH ≥ 27 μg/dL at diagnosis are 96% more likely to need a higher trilostane dosage for achieving satisfactory control of PDH. Thus, cpACTH was found to be associated with the final trilostane dose for controlling PDH in dogs.</p></div>\",\"PeriodicalId\":11356,\"journal\":{\"name\":\"Domestic animal endocrinology\",\"volume\":\"89 \",\"pages\":\"Article 106871\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2024-07-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Domestic animal endocrinology\",\"FirstCategoryId\":\"97\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0739724024000341\",\"RegionNum\":2,\"RegionCategory\":\"农林科学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"AGRICULTURE, DAIRY & ANIMAL SCIENCE\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Domestic animal endocrinology","FirstCategoryId":"97","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0739724024000341","RegionNum":2,"RegionCategory":"农林科学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"AGRICULTURE, DAIRY & ANIMAL SCIENCE","Score":null,"Total":0}
引用次数: 0

摘要

曲洛司坦是目前治疗犬垂体依赖性皮质醇增多症(PDH)的首选药物。虽然开具较高的初始剂量可能会增加先天性皮质醇分泌过少的风险,但选择更保守的方法可能会导致疾病控制延迟,因为大多数个体最终都需要增加剂量。促肾上腺皮质激素刺激试验(ACTHst)是公认的评估肾上腺功能的激素试验,是监测犬皮质醇分泌过多症(CH)药物治疗的重要工具,也可用于诊断。本研究的目的是调查 PDH 诊断时的 cpACTH 后皮质醇(cpACTH)与狗体征控制和内源性皮质醇调节所需的曲洛司坦剂量之间的关系,并假设血清 cpACTH 浓度越高,疾病控制所需的曲洛司坦剂量就越大。对 43 只 PDH 狗的诊断 cpACTH 数据进行了记录,并将其与控制临床症状和达到满意的皮质醇水平(最好为 2-7 μg/dL)所需的曲洛司坦剂量相关联。几率比(p=0.042)表明,诊断时 cpACTH ≥ 27 μg/dL 的犬需要更高的曲洛坦剂量才能达到令人满意的 PDH 控制效果的可能性要高出 96%。因此,研究发现 cpACTH 与控制犬 PDH 的最终曲洛坦剂量有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Association between post-ACTH cortisol and trilostane dosage in dogs with pituitary-dependent hypercortisolism

Trilostane is the current treatment of choice for managing pituitary-dependent hypercortisolism (PDH) in dogs. While prescribing higher initial doses may elevate the risk of iatrogenic hypocortisolism, opting for more conservative approach could result in delayed disease control, since most individuals end up requiring dosage increases. The adrenocorticotrophin stimulation test (ACTHst), a widely recognized hormonal test for assessing adrenal function, is an essential tool for monitoring the pharmacological treatment of canine hypercortisolism (CH) that can also be used for diagnostic purposes. The aim of this study was to investigate the relationship between post-ACTH cortisol (cpACTH) at PDH diagnosis and the required trilostane dose for sign control and endogenous cortisol regulation in dogs, considering a hypothesis that higher serum cpACTH concentration would necessitate a higher trilostane dosage for disease management. Data for 43 dogs with PDH had their diagnostic cpACTH recorded and correlated to the trilostane dosage necessary to control clinical signs and achieve satisfactory cortisol levels (ideally 2-7 μg/dL). The odds ratio (p=0.042) suggests that dogs with cpACTH ≥ 27 μg/dL at diagnosis are 96% more likely to need a higher trilostane dosage for achieving satisfactory control of PDH. Thus, cpACTH was found to be associated with the final trilostane dose for controlling PDH in dogs.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Domestic animal endocrinology
Domestic animal endocrinology 农林科学-奶制品与动物科学
CiteScore
5.50
自引率
4.80%
发文量
58
审稿时长
31 days
期刊介绍: Domestic Animal Endocrinology publishes scientific papers dealing with the study of the endocrine physiology of domestic animal species. Those manuscripts utilizing other species as models for clinical or production problems associated with domestic animals are also welcome. Topics covered include: Classical and reproductive endocrinology- Clinical and applied endocrinology- Regulation of hormone secretion- Hormone action- Molecular biology- Cytokines- Growth factors
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信